Catalent buys new filling tech for DPI drugs
US CMO Catalent says the purchase of Harro Hofiger Omnidose filling unit makes it a “one stop shop” for development of inhalable drugs.
The unit, which will be installed at the contract manufacturing organisations (CMOs) facility in North Carolina, enables powder filling in the 1 to 300mg into any currently available dry powder inhalation (DPI) on the market.
Catalent said that the technology will support its range of contract manufacturing services for clinical trial supplies for Phase I and II trials and provide “a scaleable path to higher volume late stage clinical and commercial manufacturing.”
The New Jersey, headquartered firm also said that the technology compliments its existing pressurised metered-dose inhaler (pMDI) inhaler manufacturing capacity.
